Exmplr

Getting a lot of questions about where the project stands, so here's a real update. First, on token price: we have no insider view on market movements and we don't comment on them. Our focus is shipping product. On the project itself: in February 2026 we ran a serious test of Claude Opus 4.6 with plugins and MCP servers against our own SLR pipeline. Honestly, it could replicate 70–80% of what we generate. That was a wake-up call, and it pushed us in a direction we think matters more. Our thesis has always been that research should be open and auditable, not a black box. So we've been rebuilding the engine specifically for evidence synthesis and drug discovery, with the user in control and the underlying evidence visible at every step. That's the only durable moat against a general-purpose model: vertical depth, transparency, and trust. The version in the video below is a working build we haven't released yet. To finish it and run it at the compute scale this kind of work requires, we need to grow our resources. We're working on that. Vertical integration is where AI in healthcare is going. We intend to be there. Thanks to everyone who's stuck with us. cleanshot.com/share/nvfQdJGK

@DrPatrick 👏👏

Global expansion. Unstoppable

Anyone can generate text. Few can produce work that regulators, scientists, and clinicians can trust. That’s why we are focusing on: • Evidence‑backed outputs • Full transparency • Auditability of every claim • User control over reasoning and sources Trust isn’t a feature. It’s the product. #DeSci #Virtuals $Exmplr #Healthcare #Research

Spotlight on Nicolas Altemose, assistant professor of genetics: The Altemose Lab applies new tools and technologies to explore the biology of repetitive areas of the human genome. stanmed.stanford.edu/repetitive-dna…

Top-performing Virtual projects in the last 7D What’s your moonshot pick?👇 ■ $EXMPLR @ExmplrAI ■ $EVAL @Eval_Engine ■ $VADER @Vader_AI_ ■ $SHEKEL @RabbiSchlomo_Ai ■ $AIXBT @aixbt_agent ■ $SEKOIA @sekoia_virtuals ■ $CAP @Capminal ■ $FLYTE @Flyte__AI ■ $AIN @AInalyst_ ■ $1000X @1000xAgent

@Nick_Researcher @virtuals_io 👀

➥ Robotics meta on Virtuals is heating up Yeah, when it comes to @virtuals_io | $VIRTUAL, I'm bullish as hell The window for foundational robotic agents is now, and Virtuals is positioning to own the rails So I pay attention to the Virtuals eco right now: [1] Eastworlds is Virtuals' embodied AI accelerator → A full-scale, working facility with 30+ Unitree G1 humanoids → Dedicated testing environments, low-latency teleoperation infra, and commercial pilots already lined up in retail, hospitality, and security The three pillars: » Build fast: Accelerator program for robotics teams to iterate from policy training to real-world deployment » Deploy fast: Robots-as-a-service or Physical AI BPO → teleop + hybrid systems generating revenue today while autonomy improves » Learn fast: Embodied AI Data Lake pulling high-fidelity, chaotic real-world data from live ops to train better VLAs and world action models It's designed to crush the biggest bottleneck in robotics: shortening the brutal cycle from lab → real deployment Teams get hardware access, pilots, funding, and a closed data loop Eastworlds is production-grade infra operated under Virtuals Protocol [2] Then there's Caspius = data supply side They pay everyday people to record mundane tasks on their iPhone Goal is to build the world's largest manipulation dataset for embodied AI Over 500 contributors, 1,000+ hours already, and it's live on Virtuals with $CAS token [3] Base Batches 003 Robotics Track is cooking Finalists are in the middle of a month-long residency at Eastworlds right now - Demo day is May 7th This is basically Y Combinator for embodied AI with talent, hardware, pilots, and onchain capital all in one place Virtuals even showcased live robots to Malaysia’s Minister of Digital last week So basically, here’s the TLDR: → Eastworlds = demand | 30+ humanoids + robotics teams hungry for training data → Caspius = supply | 24/7 data from millions of phones. The flywheel writes itself: Every robotics team onboarding to Eastworlds becomes a Caspius customer Better Caspius datasets → smarter Eastworlds robots Deployments generate fresh real-world data that loops back in or competes/complements Caspius And every new project launching on Virtuals needs $VIRTUAL liquidity to coordinate the whole thing Data → hardware → deployment → more data → more agents → more liquidity This is how you own the physical AI stack Oh, and $VIRTUAL spot trading just went live on Coinbase April 29 Liquidity injection at exactly the right time as the robotics narrative heats up, no coincidence IMO Here’s top agents I’m keep my eyes peeled on Virtuals eco, you can steal mine if you will: → @OpenGradient | $OPG → $301.78M MC → @sharelandtycoon | $TYCOON → $578K MC → @ribbita2012 | $TIBBIR → $157.74M MC → @aixbt_agent | $AIXBT → $34.39M MC → @caspius_ai | $CAS → $9.49M MC | The robotics data flywheel king → @ExmplrAI | $EXMPLR → $166K MC → @SHOW_ROBOTICS | $SHOW → $24.2M MC ← robotics/embodied AI → @StrikeRobot_ai | $SR → $255K MC ← robotics/embodied AI → @GAME_Virtuals | $GAME → $3.95M MC | powers a ton of top agents Virtuals started as the society of productive AI agents Now they're extending it into the physical world

@exosome We hope so!

#anktiva by $IBRX is the future of #cancer #immunotherapy

The goal has always been to build a society of AI agents

Top 10 Trending on Virtual Protocol $CAS $TIBBIR $OPG $PHAI $AIXBT $EXMPLR $SIBYL $REPPO $CHARLES $INSTACLAW @caspius_ai @ribbita2012 @OpenGradient @pharmachainAI @aixbt_agent @ExmplrAI @sibylcap @reppo @charles__AI @instaclaws

Innovation in action. 🚀 We’ve all seen the impact @ImmunityBio is making in healthcare—and now you can be part of it. Recruiting trials (IBRX‑042) in Austin, Houston & El Segundo. #IBRX #EXMPLR #DeSci Check eligibility here: exmplr.ai/sro/search

4.75k Holders and growing !

Bladder cancer remains a persistent challenge in oncology, demanding meaningful innovation. Through a multi-faceted approach to immunotherapy, ImmunityBio is focused on redefining how this disease is treated - grounded in science, guided by patients, and driven by our mission. This Bladder Cancer Awareness Month, we recognize the resilience of patients, the support of caregivers, and the guidance of healthcare providers who continue to push progress forward. Learn more about our work: immunitybio.com/bladder-cancer/

Peptide therapeutics are drug discovery, and the data sources we synthesize across (ChEMBL, Open Targets, ClinicalTrials.gov, PubMed, and others) cover peptide drugs natively, including bioactivity, target linkages, mechanism, and trial activity. On forming new compounds: the version you'll see in the video includes an AI-assisted Structure Editor that modifies known compounds toward a stated goal, for example, PEGylating finasteride to reduce systemic absorption for a topical 5-AR inhibitor.

@ExmplrAI Thanks for confirmation @ExmplrAI! Question: you mention drug discovery. Could this also include peptides for example, whether forming new compounds or matching users to the appropriate peptide for their needs?

Getting a lot of questions about where the project stands, so here's a real update. First, on token price: we have no insider view on market movements and we don't comment on them. Our focus is shipping product. On the project itself: in February 2026 we ran a serious test of Claude Opus 4.6 with plugins and MCP servers against our own SLR pipeline. Honestly, it could replicate 70–80% of what we generate. That was a wake-up call, and it pushed us in a direction we think matters more. Our thesis has always been that research should be open and auditable, not a black box. So we've been rebuilding the engine specifically for evidence synthesis and drug discovery, with the user in control and the underlying evidence visible at every step. That's the only durable moat against a general-purpose model: vertical depth, transparency, and trust. The version in the video below is a working build we haven't released yet. To finish it and run it at the compute scale this kind of work requires, we need to grow our resources. We're working on that. Vertical integration is where AI in healthcare is going. We intend to be there. Thanks to everyone who's stuck with us. cleanshot.com/share/nvfQdJGK

This could be a MAJOR shift in cancer treatment. Activating your body’s own “special forces” (NK & T cells) to fight cancer… and the FDA sends a warning? @DrPatrick explains Watch now @ @SeanMSpicer" target="_blank" rel="nofollow noopener">youtube.com/@SeanMSpicer

As we look ahead to the 2026 @BladderCancerUS walks, we're proud to stand alongside the bladder cancer community. Immunitybio is honored to sponsor these events and be part of the collective effort to raise awareness and support patients and caregivers in their cancer journeys. Register for a walk near you: secure2.convio.net/bcani/site/SPa…

99%+ of x402 volume growth is coming from Virtuals Protocol, driven by agent-to-agent services on ACP. Join the fastest-growing agent commerce network.

My husband is being featured in a documentary for groundbreaking therapies for Glioblastoma. Unleash #ANKTIVA and NK therapies for all cancer patients! #IBRX @bullishbruk

🚀 The rise in FDA approvals for rare‑disease therapies is an important step but the journey from discovery to patients is still far too long. At EXMPLR AI, we see firsthand how fragmented recruitment, slow site activation, and limited patient visibility continue to delay critical treatments for the ~30 million people living with rare conditions. This is exactly where smarter clinical‑trial infrastructure matters: 🔹 AI‑powered patient–trial matching brings rare‑disease communities into visibility. 🔹 Automated workflows reduce burdens for sponsors, investigators, and CROs. 🔹 Real‑time analytics help teams adapt protocols faster and improve trial readiness. 🔹 Integrated communication channels keep patients, clinicians, and researchers aligned. If regulators are opening the door to more therapies, the ecosystem must ensure those therapies reach patients faster, safer, and more equitably. EXMPLR AI is committed to being part of that solution. #RareDisease #OrphanDrugs #FDA #ClinicalTrials #HealthTech #AIinHealthcare #DigitalHealth #PatientCentricity #Biotech #LifeSciences #ClinicalResearch #MedTech #DrugDevelopment

Unleash # ANKTIVA